AMRI Signs Agreement for Exclusive License of its Tubulin Inhibitor Program for Cancer

 AMRI Signs Agreement for Exclusive License of its Tubulin Inhibitor Program
                                  for Cancer

  PR Newswire

  ALBANY, New York, Feb. 11, 2013

- Deal Affirms AMRI's Continued Efforts to Advance the Development of its
Proprietary Programs

ALBANY, New York, Feb. 11, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced
today that it has signed an exclusive license agreement with Chai
Therapeutics, LLC for the development of ALB 109564(a), AMRI's novel tubulin
inhibitor compound in late Phase I testing for the treatment of cancer. This
agreement follows the exercise of an option to license the intellectual
property, which was granted in March 2012 by AMRI to Bessor Pharma, LLC, a
translational drug development company. Chai Therapeutics is an affiliate of
Bessor Pharma, LLC.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

Under the terms of the license agreement, AMRI received an undisclosed license
fee and reimbursement for certain costs associated with the intellectual
property related to ALB 109564(a). Chai Therapeutics received an exclusive
license to the ALB 109564(a) intellectual property, and will be solely
responsible for all related research and development and patent costs going
forward; AMRI will receive a share of future consideration from the further
development and sales, if any, of any ALB 109564(a)-related drug that may be
developed, licensed and/or commercialized.

"We are very pleased to continue to work with Bessor on the further
development of AMRI's novel tubulin inhibitor," AMRI Chairman and CEO Thomas
E. D'Ambra, Ph.D. said. "The recent formation of Chai Therapeutics to focus on
the development of our compound is a strong statement by our partners of the
potential benefit that this technology could ultimately deliver to cancer
patients. Dr. Berkowitz and his team have a proven track record of success in
drug development and we are confident in their ability to move this program
forward."

D'Ambra continued, "The tubulin inhibitor program is an asset developed from
our past R&D investments. As we have stated previously, we will continue to
pursue strategic opportunities to enable AMRI to advance the clinical
development of our other compounds and programs to create near- and long-term
value for the company."

Barry A. Berkowitz, Ph.D., President and CEO of Bessor said, "In AMRI's work
to date, ALB 109564(a) has shown significant promise as a next generation
tubulin inhibitor for the treatment of cancer. Through our integrated network
of drug development and clinical experts and the flexible structure afforded
by Chai, we plan to advance the clinical program to further define the
compound's potential. ALB 109564(a) is one of several translational projects
in Bessor's growing portfolio that it is advancing to key value points."

AMRI has built a strong initial program around ALB 109564(a), providing an
early indication that it may offer clinically relevant activity distinct from
other tubulin inhibitors. This proprietary program, as well as AMRI's other
available pipeline programs in the therapeutic areas of inflammatory bowel
disease (IBD), irritable bowel syndrome (IBS), cognitive impairment and
schizophrenia, were each created with business strategies aimed at
differentiating them from existing standards of care.

About ALB 109564(a) and Oncology ALB 109564(a) is a novel analog from an
established and marketed class of tubulin inhibitors, which is designed to
kill cancer cells by preventing cell mitosis. The discovery of ALB 109564(a)
leveraged AMRI's unique biocatalysis technology platform, natural products
chemistry expertise, and high potency development capabilities. ALB 109564(a)
has significant benefits compared with existing tubulin inhibitors in the same
class. AMRI's Phase I study of ALB 109564(a) involved intravenous
administration of ALB 109564(a) to cancer patients with advanced solid tumors.
The study was designed to evaluate the compound's safety, tolerability, and
pharmacokinetic profile and document effects on tumor growth. Previously
announced results from the Phase I clinical dose-escalation study indicate
that ALB 109564(a) is well tolerated at the doses tested and shows preliminary
evidence of clinical activity in disease types not typically treated with
approved vinca alkaloids.

About AMRI Albany Molecular Research, Inc. (AMRI) is a global contract
research and manufacturing organization offering customers fully integrated
drug discovery, development and manufacturing services. For over 21 years,
AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology
industries have undergone tremendous change in response to multiple
challenges. This experience, a track record of success and locations in the
United States, Europe and Asia now provides our customers with SMARTSOURCING™,
a full range of value-added opportunities providing customers informed
decision-making, enhanced efficiency and more successful outcomes at all
stages of the pipeline. AMRI has also successfully partnered R&D programs and
is actively seeking to out-license its remaining programs for further
development. For more information about AMRI, please visit our website at
www.amriglobal.com or follow us on Twitter (@amriglobal).

About Bessor Pharma and Chai Therapeutics Bessor Pharma LLC and its affiliate,
Chai Therapeutics, LLC, founded by a team of R&D and pharmaceutical business
leaders, has created and is utilizing a new model for drug development and
value creation, with a focus on translating drug discovery/development
opportunities from universities and other organizations to key value points,
typically IND readiness and for select projects, clinical proof-of-concept.
The company has developed a flexible, project-oriented, capital efficient
approach that attacks key drug development and financing challenges while
advancing an innovative portfolio of product candidates. Bessor operates as a
semi-virtual organization with a top team of pharmaceutical R&D and business
experts and set of partners that function as a fully-integrated pharmaceutical
network.

AMRI Forward-Looking Statement This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties. Readers should not place undue
reliance on our forward-looking statements. The company's actual results may
differ materially from such forward-looking statements as a result of numerous
factors, some of which the company may not be able to predict and may not be
within the company's control. Factors that could cause such differences
include, but are not limited to: (a) Bessor Pharma's and Chai Therapeutics'
ongoing ability to raise funding for the ALB 109564(a) research and clinical
trial program; (b) problems or delays which may arise during clinical trials
or in the course of developing, testing or manufacturing these compounds that
could lead Bessor and Chai to discontinue development; (c) positive
information about early stage clinical trial results is not necessarily
indicative of clinical efficacy and does not ensure that later stage or larger
scale clinical trials will be successful, for cancer or any other indication;
(d) the planned timing of initiation and completion of clinical trials for
ALB-109564(a) are subject to the ability of Bessor and Chai to enroll
patients, enter into agreements with clinical trial sites and investigators,
and other technical hurdles and issues that may not be resolved; (e) delay or
denial of regulatory approvals from the FDA resulting from, among other
things, adverse FDA decisions or interpretations of data that differ from
AMRI, Bessor or Chai's interpretations and that may require additional
clinical trials or potential changes in the cost, scope and duration of
clinical trials; and those factors discussed in AMRI's Annual Report on Form
10-K for the year ended December 31, 2011 as filed with the Securities and
Exchange Commission, and the company's other SEC filings. The company does not
undertake any obligation to and does not intend to update any forward-looking
statements contained in this press release.

Website: http://www.amriglobal.com
Contact: Investors, Michael Nolan, AMRI Chief Financial Officer,
+1-518-512-2261, Media, Gina Monari, AMRI Communications, +1-518-512-2512; For
Bessor Pharma, Robert Gottlieb, RMG Associates, LLC, +1-857-891-9091